Exelixis | Sustainability Performance
Exelixis is focused on the discovery, development, and commercialization of cancer treatments. The company works on advancing therapies aimed at addressing unmet medical needs in oncology, emphasizing innovation and improving patient outcomes.
1994
United States
1,001 - 5,000 employees
Biotechnology
$1B - 10B in revenue
$500M - 1B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#7873
Overallⓘ#1814
in United Statesⓘ#178
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Digital emissionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Exelixis has faced multiple US patent disputes over its Cabometyx kidney cancer drug including the controversial 2022 MSN Pharmaceuticals generic challenge, plus periodic class actions over inadequate disclosure of clinical trial results affecting share price.
